Why the study?
The optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial.
Do different antiplatelet strategies (high-potency, high- to low-potency, low-dose, or short-duration DAPT) improve cardiovascular and bleeding outcomes compared to 12-month aspirin and clopidogrel DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Do different antiplatelet strategies (high-potency, high- to low-potency, low-dose, or short-duration DAPT) improve cardiovascular and bleeding outcomes compared to 12-month aspirin and clopidogrel DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
A high- to low-potency DAPT strategy (aspirin and ticagrelor for 3 months followed by aspirin and clopidogrel) reduces major adverse cardiovascular events without increasing major bleeding in patients with ACS undergoing PCI.
BACKGROUND: Optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial. METHODS AND RESULTS: Digital databases (PubMed, Cochrane, and Embase) were queried to select all randomized controlled trials on a post-percutaneous coronary intervention population with acute coronary syndrome. Dual-antiplatelet therapy (DAPT) with aspirin and clopidogrel for 12 months was compared with 4 major strategies: high-potency, high- to low-potency, low-dose, and short-duration DAPT. A network meta-analysis was performed to compare the safety and efficacy of different antiplatelet strategies. This study was the second updated manuscript under the International Prospective Register of Systematic Review registration (CRD42021286552). Thirty-two randomized controlled trials comprising 103 459 (51 750 experimental, 51 709 control) patients were included. Compared with DAPT with aspirin and clopidogrel for 12 months, high- to low-potency DAPT (risk ratio [RR], 0.69 [95% CI, 0.52-0.92]) and aspirin+prasugrel containing DAPT for 12 months (RR, 0.84 [95% CI, 0.72-0.98]) had a significantly lower, whereas DAPT for 1 month followed by clopidogrel only (RR, 1.59 [95% CI, 1.06-2.39]) had a higher, incidence of major adverse cardiovascular events at 1 year (median follow-up). Prasugrel (RR, 1.35 [95% CI, 1.09-1.66]) and ticagrelor (RR, 1.38 [95% CI, 1.17-1.62]) containing DAPT for 12 months had significantly higher rates, whereas high- to low-potency DAPT (RR, 0.85 [95% CI, 0.63-1.15]) had no significant risk of major bleeding. CONCLUSIONS: Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post-percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Ullah et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: